Source: http://www.google.com/patents/US8063182?dq=inassignee:doubleclick
Timestamp: 2017-11-18 09:01:24
Document Index: 59328826

Matched Legal Cases: ['§119', '§119', 'Application No. 90107393', 'Application No. 90107393', 'Application No. 108967', 'Application No. 99']

Patent US8063182 - Human TNF receptor fusion protein - Google Patents
The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions),...http://www.google.com/patents/US8063182?utm_source=gb-gplus-sharePatent US8063182 - Human TNF receptor fusion protein
Publication number US8063182 B1
Application number US 08/444,790
Also published as US8163522
Publication number 08444790, 444790, US 8063182 B1, US 8063182B1, US-B1-8063182, US8063182 B1, US8063182B1
Inventors Manfred Brockhaus, Reiner Gentz, Dembic Zlatko, Werner Lesslauer, Hansruedi Lotscher, Ernst-Jurgen Schlaeger
Original Assignee Hoffman-Laroche Inc.
Patent Citations (105), Non-Patent Citations (254), Referenced by (7), Classifications (16), Legal Events (2)
Human TNF receptor fusion protein
US 8063182 B1
This is a division of application Ser. No. 08/095,640, filed Jul. 21, 1993; now U.S. Pat. No. 5,610,279, which is a continuation application of Ser. No. 07/580,013, filed Sep. 10, 1990, now abandoned. This application claims priority under 35 U.S.C. §119 to application Serial Numbers 3319/89, 746/90 and 1347/90, filed on Sep. 12, 1989, Mar. 8, 1990 and Apr. 20, 1990, respectively, all in Switzerland. This application also claims priority under 35 U.S.C. §119 to European Patent Application Number 90116707.2—(now Patent Number EP 0417563), filed Aug. 31, 1990.
Tumor necrosis factor α (TNFα, also cachectin), discovered as a result of its hemorragic-necrotizing activity on certain tumors, and lymphotoxin (TNFβ) are two closely related peptide factors [3] from the class of lymphokines/cytokines which are both referred to herein-after as TNF [see references 2 and 3]. TNF possesses a broad cellular spectrum of activity. For example, TNF has inhibitory or cytotoxic activity on a series of tumor cell lines [2,3], stimulates the proliferation of fibroblasts and the phagocytic/cytotoxic activity of myeloic cells [4, 5, 6], induces adhesion molecules in endothelial cells or exerts an inhibitory activity on the endothelium [7, 8, 9, 10], inhibits the synthesis of specific enzymes in adipocytes [11] and induces the expression of histo-compatibility antigens [12]. Many of these TNF activities are produced via induction of other factors or by synergistic effects with other factors such as interferons or interleukins [13-16].
FIG. 1. Nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) for cDNA clone derived from 55 kD TNF-BP. The 19 amino acid transmembrane region is underlined. Hypothetical glycosylation sites are identified by asterisks.
(IID) Leu-pro-Ala-Gln-Val-Ala-Phe-X-Pro-Tyr-Ala-Pro-Glu-Pro-Gly-Ser-Thr-Cys (SEQ ID NO: 10)
A process for the isolation of the TNF-BP in accordance with the invention is also an object of the present invention. This process comprises carrying out essentially the following purification steps in sequence: production of a cell or tissue extract, immune affinity chromatography and/or single or multiple ligand affinity chromatography, high resolution liquid chromatography (HPLC) and preparative SDS-polyacrylamide gel electro phoresis (SDS-PAGE). The combination of the individual purification steps, which are known from the state of the art, is essential to the success of the process in accordance with the invention, whereby individual steps have been modified and improved having regard to the problem to be solved. Thus, for example, the original combined immune affinity chromatography/TNFα-ligand affinity chromatography step originally used for the enrichment of TNF-BP from human placenta [31] has been altered by using a BSA-Sepharose 4B pre-column. For the application of the cell or membrane extract, this pre-column was connected in series with the immune affinity column followed by the ligand affinity column. After the application of the extract the two afore-mentioned columns were coupled, each eluted and the TNF-BP-active fractions were purified again via a ligand affinity column. The use of a detergent-containing solvent mixture for the performance of the reversed-phase HPLC step is essential to the invention.
The present invention is also concerned with the recombinant proteins coded by any of DNA sequences described above. Of course, there are thereby also included such proteins in whose amino acid sequences amino acids have been exchanged, for example by planned mutagenesis, so that the activity of the TNF-BP or fragments thereof, namely the binding of TNF or the interaction with other membrane components participating in the signal transfer, have been altered or maintained in a desirable manner. Amino acid exchanges in proteins and peptides which do not generally alter the activity of such molecules are known in the state of the art and are described, for example, by H. Neurath and R. L. Hill in “The'Proteins” (Academic Press, New York, 1979, see especially FIG. 6, page 14). The most commonly occurring exchanges are: Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly as well as these in reverse. The present invention is also concerned with vectors which contain any of the DNA sequences described above in accordance with the invention and which are suitable for the transformation of suitable pro- and eukaryotic host systems, whereby there are preferred those vectors whose use leads to the expression of the proteins which are coded by any of the DNA sequences described above in accordance with the invention. Finally, the present invention is also concerned with pro- and eukaryotic host systems transformed with such vectors, as well as a process for the production of recombinant compounds in accordance with the invention by cultivating such host systems and subsequently isolating these compounds from the host systems themselves or their culture supernatants.
Starting from the thus-obtained amino acid sequence information or the DNA and amino acid sequences given in FIG. 1 as well as in FIG. 4 there can be produced, taking into consideration the degeneracy of the genetic code, according to methods known in the state of the art suitable oligonucleotides [51]. By means of these, again according to known methods of molecular biology [42,43], cDNA or genomic DNA banks can be searched for clones which contain nucleic acid sequences coding for TNF-BP. More-over, using the polymerase chain reaction (PCR) [49] cDNA fragments can be cloned by completely degenerating the amino acid sequence of two spaced apart relatively short segments while taking into consideration the genetic code and introducing into their complementarity suitable oligo-nucleotides as a “primer”, whereby the fragment lying between these two sequences can be amplified and identified. The determination of the nucleotide sequence of a such a fragment permits an independent determination of the amino acid sequence of the protein fragment for which it codes. The cDNA fragments obtainable by PCR can also, as already described for the oligonucleotides themselves, be used according to known methods to search for clones containing nucleic acid sequences coding for TNF-BP from cDNA or genomic DNA banks. Such nucleic acid sequences can then be sequenced according to known methods [42]. On the basis of the thus-determined sequences and of the already known sequences for certain receptors, those partial sequences which code for soluble TNF-BP fragments can be determined and cut out from the complete sequence using known methods [42].
Suitable expression vectors include, for example, vectors such as pBC12MI [ATCC 67 109], pSV2dhfr [ATCC 37 146], pSVL [Pharmacia, Uppsala, Sweden], pRSVcat [ATCC 37 152] and pMSG [Pharmacia, Uppsala, Sweden]. The vectors “pK19” and “pN123” used in Example 9 are especially preferred vectors. These can be isolated according to known methods from E. coli strains HB101(pK19) and HB101(pN123) transformed with them [42]. These E. coli strains have been deposited on the 26 Jan. 1990 at the Deutschen Sammlung von Mikroorganismen and Zellkulturen GmbH (DSM) in Braunschweig, FRG, under DSM 5761 for HB101(pK19) and DMS 5764 for HB101(pN123). For the expression of proteins which consist of a soluble fragment of non-soluble TNF-BP and an immunoglobulin fragment, i.e. all domains except the first of the constant region of the heavy chain, there are especially suitable pSV2-derived vectors as described, for example, by German, C. in “DNA Cloning” [Vol. II., edt. by Glover, D. M., IRL Press, Oxford, 1985]. The vectors pCD4-Hp (DSM 5315, deposited on 21 Apr. 1989), pDC4-Hγ1 (DSM 5314, deposited on 21 Apr. 1989) and pCD4-Hy3 (DSM 5523, deposited on 14 Sep. 1989) which have been deposited at the Deutschen Sammlung von Mikroorganismen and Zellkulturen GmbH (DSM) in Braunschweig, FRG, and which are described in detail in European Patent Application No. 90107393.2 are especially preferred vectors. This European Patent Specification and the equivalent Applications referred to in Example 11 also contain data with respect to the further use of these vectors for the expression of chimeric proteins (see also Example 11) and for the construction of vectors for the expression of such chimeric proteins with other immunoglobulin fragments.
The manner in which these cells are transfected depends on the chosen expression system and vector system. An overview of these methods is to be found e.g. in Pollard et al., “DNA Transformation of Mammalian Cells” in “Methods in Molecular Biology” [Nucleic Acids Vol. 2, 1984, Walker, J. M., ed, Humana, Clifton, N.J. ]. Further methods are to be found in Chen and Okayama [“High-Efficiency Transformation of Mammalian Cells by Plasmid DNA”, Molecular and Cell Biology 7, 2745-2752, 1987] and in Feigner [Feigner et al., “Lipofectin: A highly efficient, lipid-mediated. DNA-transfection procedure”, Proc. Nat. Acad. Sci. USA 84, 7413-7417, 1987].
The baculovirus expression system, which has already been used successfully for the expression of a series of proteins (for an overview see Luckow and Summers, Bio/Technology 6, 47-55, 1988), can be used for the expression in insect cells. Recombinant proteins can be produced in authentic form or as fusion proteins. The thus-produced proteins can also be modified such as, for example, glycosylated (Smith et al., Proc. Nat. Acad. Sci. USA 82, 8404-8408, 1987). For the production of a recombinant baculovirus which expresses the desired protein there is used a so-called “transfer vector”. Under this there is to be understood a plasmid which contains the heterologous DNA sequence under the control of a strong promoter, e.g. that of the polyhedron gene, whereby this is surrounded on both sides by viral sequences. The vectors “pN113”, “pN119” and “pN124” used in Example 10 are especially preferred vectors. These can be isolated according to known methods from E. coli strains HB101(pN113), HB101(pN119) and HB101(pN124) transformed with them. These E. coli strains have been deposited on the 26 Jan. 1990 at the Deutschen Sammlung von Mikroorganismen and Zellkulturen GmbH (DSM) in Braunschweig, FRG, under DSM 5762 for HB101(pN113), DSM 5763 for HB101(pN119) and DSM 5765 for HB101(pN124). The transfer vector is then transfected into the insect cells together with DNA of the wild type baculovirus. The recombinant viruses which result in the cells by homologous recombination can then be identified and isolated according to known methods. An overview of the baculovirus expression system and the methods used therein is to be found in Luckow and Summers [52].
On the basis of the high binding affinity of TNF-BP in accordance with the invention for TNF (Kd value in the order of 10−9-10−10 M), these or fragments thereof can be used as diagnostics for the detection of TNF in serum or other body fluids according to methods known in the state of the art, for example in solid phase binding tests or in combination with anti-TNF-BP antibodies in so-called “sandwich” tests.
The TNF-BP were detected in a filter test with human radioiodinated 125I-TNF. TNF (46, 47) was radioactively labelled with Na125I (IMS40, Amersham, Amersham, England) and iodo gene (#28600, Pierce Eurochemie, Oud-Beijerland, Netherlands) according to Fraker and Speck [48]. For the detection of the TNF-BP, isolated membranes of the cells or their solubilized, enriched and purified fractions were applied to moist nitrocellulose filter (0.45μ, BioRad, Richmond, Calif., USA). The filters were then blocked in buffer solution with 1% skimmed milk powder and subsequently incubated with 5·105 cpm/ml of 125I-TNFα (0.3-1.0·108 cpm/μg) in two batches with and without the addition of 5 μg/ml of non-labelled TNFα, washed and dried in the air. The bound radio-activity was detected semiquantitatively by autoradiography or counted in a gamma-counter. The specific 125I-TNF-α binding was determined after correction for unspecific binding in the presence of unlabelled TNF-α in excess. The specific TNF-binding in the filter test was measured at various TNF concentrations and analyzed according to Scatchard, whereby a Kd value of ·10−9-10−10 M was determined.
HL60 cells [ATCC No. CCL 240] were cultivated on an experimental laboratory scale in a RPMI 1640 medium [GIBCO catalogue No. 074-01800], which contained 2 g/l NaHCO3 and 5% foetal calf serum, in a 5% CO2 atmosphere, and subsequently centrifuged.
The following procedure was used to produce high cell densities on an industrial scale. The cultivation was carried out in a 75 l Airlift fermenter (Fa. Chemap, Switzerland) with a working volume of 58 l. For this there was used the cassette membrane system “PROSTAK” (Millipore, Switzerland) with a membrane surface of 0.32 m2(1 cassette) integrated into the external circulation circuit. The culture medium (see Table 1) was pumped around with a Watson-Marlow pump, Type 603U, with 5 l/min. After a steam sterilization of the installation, whereby the “PROSTAK” system was sterilized separately in autoclaves, the fermentation was started with growing HL-60 cells from a 20 l Airlift fermenter (Chemap). The cell cultivation in the inoculation fermenter was effected in a conventional batch process in the medium according to Table 1 and an initial cell titre of 2×105 cells/ml. After 4 days the HL60 batch was transferred with a titre of 4.9×106 cells/ml into the 75 l fermenter. The pH value was held at 7.1 and the pO2 value was held at 25% saturation, whereby the oxygen introduction was effected through a microporous frit. After initial batch fermentation, on the 2nd day the perfusion at a cell titre of 4×106 cells/ml was started with 30 l of medium exchange per day. On the filtrate side of the medium the conditioned medium was removed and replaced by the addition of fresh medium. The added medium was fortified as follows: Primatone from 0.25% to 0.35%, glutamine from 5 mM to 6 mM and glucose from 4 g/l to 6 g/l. The perfusion rate was then increased on the 3rd and 4th day to 72 l of medium/day and on the 5th day to 100 l of medium/day. The fermentation had finished after 120 hours of continuous cultivation. Exponential cell growth up to 40×106 cells/ml took place under the given fermentation conditions. The duplication time of the cell population was 20-22 hours to 10×106 cells/ml and then increased to 30-36 hours with increasing cell density. The proportion of living cells lay at 90-95% during the entire fermentation period. The HL-60 batch was then cooled down in the fermenter to about 12° C. and the cells were harvested by centrifugation (Beckman centrifuge [Model J-6B, Rotor JS], 3000 rpm, 10 min., 4° C.).
Ca(NO3)2 • 4H2O 20
CuSO4 • 5H2O 0.498 · 10−3
Fe(NO3)3 • 9H2O 0.02
FeSO4 • 7H2O 0.1668
NaH2PO4 • H2O 75
Na2SeO3 • 5H2O 9.6 · 10−3
ZnSO4 • 7H2O 0.1726
L-Cysteine HCl • H2O 7.024
L-Histidine HCl • H2O 27.392
L-Tyrosine • 2Na 69.76
Tranferrin (human) 15 μg/ml
Bovine serum albumin 67 μg/ml
Primatone RL (Sheffield Products, 0.25%
Pluronic F68 0.01%
The centrifugate was washed with isotonic phosphate buffer (PBS; 0.2 g/l KCl, 0.2 g/l KH2PO4, 8.0 g/1 NaCl, 2.16 g/l Na2HPO4.7H20), which had been treated with 5% dimethylformamide, 10 mM benzamidine, 100 U/ml aprotinin, 10 μM leupeptin, 1 μM pepstatin, 1 mM o-phenanthroline, 5 mM iodoacetamide, 1 mM phenyl-methylsulphonyl fluoride (referred to hereinafter as PBS-M). The washed cells were extracted at a density of 2.5·108 cells/ml in PBS-M with Triton X-100 (final concentration 1.0%). The cell extract was clarified by centrifugation (15,000×g, 1 hour; 100,000×g, 1 hour).
A centrifugation supernatant from the cultivation of HL60 cells on an experimental laboratory scale, obtained according to Example 2, was diluted with PBS in the ratio 1:10. The diluted supernatant was applied at 4° C. (flow rate: 0.2 ml/min.) to a column which contained 2 ml of Affigel 10 (Bio Rad Catalogue No. 153-6099) to which had been coupled 20 mg of recombinant human TNF-α [Pennica, D. et al. (1984) Nature 312, 724; Shirai, T. et al. (1985) Nature 313, 803; Wang, A. M. et al. (1985) Science 228, 149] according to the recommendations of the manufacturer. The column was washed at 4° C. and a throughflow rate of 1 ml/min firstly with 20 ml of PBS which contained 0.1% Triton X 114 and thereafter with 20 ml of PBS. Thus-1-enriched TNF-BP was eluted at 22° C. and a flow rate of 2 ml/min with 4 ml of 100 mM glycine, pH 2.8, 0.1% decyl-maltoside. The eluate was concentrated to 10 μl in a Centricon 30 unit [Amicon].
The immunized mice were sacrificed on day 14, the popliteal lymph nodes were removed, minced and suspended by repeated pipetting in Iscove's medium (IMEM, GIBCO Catalogue No. 074-2200) which contained 2 g/l NaHCO3. According to a modified procedure of De St. Groth and Scheidegger [J. Immunol. Methods (1980), 35, 1] 5×107 cells of the lymph nodes were fused with 5×107PAI mouse myeloma cells (J. W. Stocker et al., Research Disclosure, 217, May 1982, 155-157) which were in logarithmic growth. The cells were mixed, collected by centrifugation and resuspended in 2 ml of 50% (v/v) polyethylene glycol in IMEM at room temperature by slight shaking and diluted by the slow addition of 10 ml of IMEM during careful shaking for 10 minutes. The cells were collected by centrifugation and resuspended in 200 ml of complete medium [IMEM+20% foetal calf serum, glutamine (2.0 mM), 2-mercaptoethanol (100 μl), 100 μM hypoxanthine, 0.4 μM aminopterine and 16 μM thymidine (HAT)]. The suspension was distributed on 10 tissue 10 culture dishes each containing 96 wells and incubated at 37° C. for 11 days without changing the medium in an atmosphere of 5% CO2 and a relative humidity of 98%.
The antibodies are distinguished by their inhibitory action on the binding of TNF to HL60 cells or by their binding to antigens in the filter test according to Example 1. The following procedure was used to detect the biological activity of anti(TNF-BP) antibodies: 5×106 HL60 or U937 cells were incubated in complete RPMI 1640 medium together with affinity-purified monoclonal anti-(TNF-BP) antibodies or control antibodies (i.e. those which are not directed against TNF-BP) in a concentration range of 1 ng/ml to 10 μg/ml. After incubation at 37° C. for one hour the cells were collected by centrifugition and washed with 4.5 ml of PBS at 0° C. They were resuspended in 1 ml of complete RPMI 1640 medium (Example 2) which additionally contained 0.1% sodium azide and 125I-TNFα (106 cpm/ml) with or without the addition of unlabelled TNFα (see above). The specific radioactivity of the 125I-TNFα amounted to 700 Ci/mmol. The cells were incubated at 4° C. for 2 hours, collected and washed 4 times at 0° C. with 4.5 ml of PBS which contained 1% BSA and 0.001% Triton X 100 (Fluka). The radioactivity bound to the cells was measured in a γ-scintillation counter. The cell-bound radioactivity of cells which had not been treated with anti-(TNF-BP) antibodies was determined in a comparative experiment (approximately 10 000 cpm/5×106 cells).
For the further purification, a monoclonal anti-(55 kD TNF-BP) antibody (2.8 mg/ml gel), obtained according to Example 3, TNFα (3.9 mg/ml gel) and bovine serum albumin (BSA, 8.5 mg/ml gel) were each covalently coupled to CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) according to the directions of the manufacturer. The cell extract obtained according to Example 2 was passed through the thus-prepared columns which were connected in series in the following sequence: BSA-Sepharose pre-column, immune affinity column (anti-(55 kD-TNF-BP) antibody), TNFα-ligand affinity column. After completion of the application the two last-mentioned columns were separated and washed individually with in each case 100 ml of the following buffer solutions: (1) PBS, 1,0% Triton X-100, 10 mM benzamidine, 100 U/ml aprotinin; (2) PBS, 0.1% Triton X-100, 0.5M NaCl, 10 mM ATP, 10 mM benzamidine, 100 U/ml aprotinin; and (3) PBS, 0.1% Triton X-100, 10 mM benzamidine, 100 U/ml aprotinin. Not only the immune affinity column, but also the TNFα-ligand affinity column were then each eluted with 100 mM glycine pH 2.5, 100 mM NaCl, 0.2% decylmaltoside, 10 mM benzamidine, 100 U/ml aprotinin. The fractions of each column which were active in the filter test according to Example 1 were thereafter combined and neutralized with 1M Tris pH 8.0.
For the amino acid sequence analysis, the fractions which had been obtained according to Example 5 and which were active according to the filter test (Example 1) were separated using the SDS-PAGE conditions described in Example 6, but now reducing (SDS sample buffer with 125 mM dithiothreitol). The same bands as in Example 6 were found, but because of the reducing conditions of the SDS-PAGE in comparison to Example 6 all showed an about 1-2 kD higher molecular weight. These bands were then transferred according to Example 6 on to PVDF membranes and stained with 0.15% Serva-Blue in methanol/water/glacial acetic acid (50/400/10 parts by volume) for 1 minute, decolorized with methanol/water/glacial acetic acid (45/48/7 parts by volume), rinsed with water, dried in air and thereafter cut out. The conditions given by Hunkapiller [34] were adhered to in all steps in order to avoid N-terminal blocking. Initially, the purified TNF-BP were used unaltered for the amino acid sequencing. In order to obtain additional sequence information, the TNF-BP after reduction and S-carboxymethylation [Jones, B. N. (1986) in “Methods of Protein Micro-characterisation”, J. E. Shively, ed., Humana Press, Clifton N.J., 124-125] were cleaved with cyanogen bromide (Tarr, G. E. in “Methods of Protein Microcharacterisation”, 165-166, loc. cit.), trypsin and/or proteinase K and the peptides were separated by HPLC according to known methods of protein chemistry. Thus-prepared samples were then sequenced in an automatic gas phase microsequencing apparatus (Applied Biosystems Model 470A, ABI, Foster City, Calif., USA) with an on-line automatic HPLC PTH amino acid analyzer (Applied Biosystems Model 120, ABI see above) connected to the outlet, whereby the following amino acid sequences were determined:
Val-Pro-His-Leu-Pro-Ala-Asp (SEQ ID NO: 13)
Gly-Ser-Gln-Gly-Pro-Glu-Gln-Gln-X-X-Leu-Ile-X-Ala-Pro (SEQ ID NO: 14), in which X stands for an amino acid residue which could not be determined.
Starting from the amino acid sequence according to formula IA there were synthesized having regard to the genetic code for the amino acid residues 2-7 and 17-23 corresponding completely degenerated oligonucleotides in suitable complementarity (“sense” and “antisense” oligonucleotides). Total cellular RNA was isolated from HL60 cells [42,43] and the first cDNA strand was synthesized by oligo-dT priming or by priming with the “antisense” oligonucleotide using a cDNA synthesis kit (RPN 1256, Amersham, Amersham; England) according to the instructions of the manufacturer. This cDNA strand and the two synthesized degenerate “sense” and “anti-sense” oligonucleotides were used in a polymerase chain reaction (PCR, Perkin Elmer Cetus, Norwalk, Conn., USA according to the instructions of the manufacturer) to synthesize as a cDNA fragment the base sequence coding for the amino acid residues 8-16 (formula IA). The base sequence of this cDNA fragment accorded to: 5′-AGGGAGAAGAGAGATAGTGTGTGTCCC-3′ (SEQ ID NO: 16). This cDNA fragment was used as a probe in order to identify according to a known procedure a cDNA clone coding for the 55 kD TNF-BP in a Xgt11-cDNA gene bank from human placenta (42, 43). This clone was then cut according to usual methods from the X-vector and cloned in the plasmids pUC18 (Pharmacia, Uppsala, Sweden) and pUC19 (Pharmacia, Uppsala, Sweden) and in the M13 mp 18/M13 mp 19 bacteriophage (Pharmacia, Uppsala, Sweden) (42, 43). The nucleotide sequence of this cDNA clone was determined using a Sequenase kit (U.S. Biochemical, Cleveland, Ohio, USA) according to the details of the manufacturer. The nucleotide sequence and the amino acid sequence derived therefrom for the 55 kD TNF-BP and its signal peptide (amino acid “−28” to amino acid “0”) is given in FIG. 1 using the abbreviations for bases such as amino acids usual in the state of the art. From sequence comparisons with other already known receptor protein sequences there can be determined a N-terminal domain containing approximately 180 amino acids and a C-terminal domain containing 220 amino acids which are separated from one another by a transmembrane region of 19 amino acids (underlined in FIG. 1) which is typical according to the sequence comparisons. Hypothetical glycosylation sites are characterized in FIG. 1 by asterisks above the corresponding amino acid.
Essentially analogous techniques were used to identify 75/65 kD TNF-BP-coding partial cDNA sequences, whereby however, in this case genomic human DNA and completely degenerated 14-mer and 15-mer “sense” and “antisense” oligonucleotides derived from peptide IIA were used in order to produce a primary 26 by cDNA probe in a polymerase chain reaction. This cDNA probe was then used in a HL-60 cDNA library to identify cDNA clones of different lengths. This cDNA library was produced using isolated HL60 RNA and a cDNA cloning kit (Amersham) according to the details of the manufacturer. The sequence of such a cDNA clone is given in FIG. 4, whereby repeated sequencing lead to the following correction. A threonine coded by “ACC” not “TCC”, has to be at position 3 instead of the serine.
Vectors starting from the plasmid “pN11” were constructed for the expression in COS cells. The plasmid “pN11” contains the efficient promoter and enhancer of the “major immediate-early” gene of human cytomegalovirus (“HCMV”; Boshart et al., Cell 41, 521-530, 1985). After the promoter there is situated a short DNA sequence which contains several restriction cleavage sites, which are present only once in the plasmid (“polylinker”), inter alia the cleavage sites for HindIII, BalI, BamHI and PvuII (see sequence).
For the construction of the expression vector “pN123”, this plasmid “pN11” was cleaved the restriction endo-nuclease PvuII and subsequently treated with alkaline phosphatase. The dephosphorylated vector was thereafter isolated from an agarose gel (V1). The 5′-projecting nucleotides of the EcoRI-cleaved 1.3 kb fragment of the 55 kD TNF-BP-cDNA (see Example 8) were filled in using Klenow enzyme. Subsequently, this fragment was isolated from an agarose gel (F1). Thereafter, V1 and F1 were joined together using T4-ligase. E. coli HB101 cells were then transformed with this ligation batch according to known methods [42]. By means of restriction analyses and DNA sequencing according to known methods [42] there were identified transformants which had been transformed with a plasmid and which contained the 1.3 kb EcoRI fragment of the 55 kD TNF-BP-cDNA in the correct orientation for expression via the HCMV-promoter. This vector received the designation “pN123”.
BAMHI 5′-CACAGGGATCCATAGCTGTCTGGCATGGGCCTCTCCAC-3′ (SEQ ID NO: 19) ASP718
Transfection of the COS cells with the plasmids “pN123” or “pK19” was carried out according to the lipofection method published by Feigner et al. (Proc. Natl. Acad. Sci. USA 84, 7413-7417, 1987). 72 hours after the transfection had been effected the cells transfected with “pN123” were analyzed for binding with 125I-TNFα according to known methods. The results of the Scatchard analysis [Scatchard, G., Ann. N.Y. Acad. Sci. 51, 660, 1949] of the thus-obtained binding data (FIG. 2A) is given in FIG. 2B. The culture supernatants of the cells transfected with “pK19” were investigated in a “sandwich” test. For this purpose, PVC microtitre plates (Dynatech, Arlington, Va., USA) were sensitized with 100 μl/well of a rabbit-anti-mouse immunoglobulin (10 μg/ml PBS). Subsequently, the plates were washed and incubated (3 hours, 20° C.) with an anti-55 kD TNF-BP antibody which had been detected by its antigen binding and isolated according to Example 3, but which did not inhibit the TNF-binding to cells. The plates were then again washed and incubated overnight at 4° C. with 100 μl/well of the culture supernatant (diluted 1:4 with buffer A containing 1% skimmed milk powder: 50 mM Tris/HCl pH 7.4, 140 mM NaCl, 5 mM EDTA, 0.02% Na azide). The plates were emptied and incubated at 4° C. for 2 hours with buffer A containing 125I-TNFα (106 cpm/ml, 100 μl/well) with or without the addition of 2 μg/ml of unlabelled TNF. Thereafter, the plates were washed 4 times with PBS, the individual wells were cut out and measured in a λ-counter. The results of 5 parallel transfections (columns # 2, 3, 4, 6 and 7), of two control transfections
E. coli HB101 was transformed with the ligation batch and transformants containing a plasmid in which the oligonucleotide had been incorporated correctly were identified by restriction analysis and DNA sequencing according to known methods (see above); this plasmid was named “pNR704”. For the construction of the transfer vector “pN113”, this plasmid “pNR704” was cleaved with EcoRI, treated with alkaline phosphatase and the thus-1-produced vector trunk (V2) was subsequently isolated from an agarose gel. The 1.3 kb fragment of the 55 kD TNF-BP-cDNA cleaved with EcoRI as above was ligated with fragment V2. Transformants obtained with this ligation batch, which contained a plasmid containing the cDNA insert in the correct orientation for the expression via the polyhedron promoter, were identified (see above). The vector isolated therefrom received the designation “pN113”.
Two stop codons of the translation after amino acid 182 and a cleavage site for the restriction endo-nuclease Asp718 are incorporated with the above adaptor. After carrying out ligation the batch was digested with EcoRI and Asp718 and the partial 55 kD TNF-BP fragment (F3) was isolated. Furthermore, the plasmid “pNR704”, likewise cleaved with Asp718 and EcoRI, was ligated with F3 and the ligation batch was transformed into E. coli HB101. The identification of the transformants which contained a plasmid in which the partial 55 kD TNF-BP cDNA had been correctly integrated for the expression was effected as already described. The plasmid isolated from these transformants received the name “pN119”.
The following procedure was used for the construction of the transfer vector “pN124”. The cDNA fragment coding for the extracellular part of the 55 kD TNF-BP, described in Example 9, was amplified with the specified oligo-nucleotides with the aid of PCR technology as described in Example 9. This fragment was cleaved with BamHI and Asp718 and isolated from an agarose gel (F4). The plasmid “pNR704” was also cleaved with BamHI and Asp718 and the vector trunk (V4) was isolated (see above). The fragments V4 and F4 were ligated, E. coli HB101 was transformed therewith and the recombinant transfer vector “pN124” was identified and isolated as described.
The following procedure was used for the transfection 10 of the insect cells. 3 μg of the transfer vector “pN113” were transfected with 1 μg of DNA of the Autographa californica nuclear polyhedrosisvirus (AcMNPV) (EP 127839) in Sf9 cells (ATCC CRL 1711). Polyhedron-negative viruses were identified and purified from “plaques” [52]. Sf9 cells were again infected with these recombinant viruses as described in [52]. After 3 days in the culture the infected cells were investigated for TNF-binding using 125I-TNFα. For this purpose, the transfected cells were washed from the cell culture dish with a Pasteur pipette and resuspended at a cell density of 5×106 cells/ml of culture medium [52] which contained 10 ng/ml of 125I-TNF-α, not only in the presence of, but also in the absence of 5 μg/ml of non-labelled TNF-α and incubated on ice for 2 hours. Thereafter, the cells were washed with pure culture medium and the cell-bound radio-activity was counted in a γ-counter (see Table 2).
Non-infected cells 60 cpm
This cDNA fragment was ligated in the pCD4-Hy3 vector [DSM 5523; European Patent Application No. 90107393.2; Japanese Patent Application No. 108967/90; U.S. Pat. No. 51,077,390] from which the CD4-cDNA had been removed via the SstI restriction cleavage sites. SstI cleavage sites are situated in vector pCD4-Hγ3 not only in front of, but also behind the CD4-partial sequence fragment. The construction was transfixed in J558 myeloma cells (ATCC No. TIB6) by means of protoplast fusion according to Oi et al. (Procd. Natl. Acad. Sci. USA 80, 825-829, 1983). Transfectants were selected by adding 5 μg/ml of mycophenolic acid and 250 g/ml of xanthin (Traunecker et al., Eur. J. Immunol. 16, 851-854 [1986]) in basic medium (Dulbecco's modified Eagle's Medium, 10% foetal calf serum, 5×10−5M 2-mercaptoethanol). The expression product secreted by the transfixed cells could be purified using usual methods of protein chemistry, e.g. TNF-BP-antibody affinity chromatography. Unless not already specifically indicated, standard procedures as described e.g. by Freshney, R. I. in “Culture of Animal Cells”, Alan R. Liss, Inc., New York (1983) were used for the cultivation of the cell lines employed, for the cloning, for the selection or for the expansion of the cloned cells.
1. G. E. Nedwin, S. L. Naylor, A. Y. Sakaguchi, D. Smith, Jarrett-Nedwin, D. Pennica, D. V. Goeddel and P. W. Gray: Nucl. Acids Res. 12, 6361, 1985
14. J. W. Lowenthal, D. W. Ballard, E. B•hnlein and W. C. Greene: Proc. Natl. Acad. Sci. USA ja, 2331, 1989
US4729326 Oct 17, 1986 Mar 8, 1988 Allgemeiner Brandschutz G.u.M. Breivogel GmbH Walk-in shelter
US4769326 Apr 12, 1984 Sep 6, 1988 The Regents Of The University Of California Expression linkers
US4770995 Aug 29, 1985 Sep 13, 1988 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
US4894439 May 22, 1986 Jan 16, 1990 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4912044 Oct 3, 1986 Mar 27, 1990 Basf Aktiengesellschaft Preparation of mesophilic microorganisms which contain a D-hydantoinase which is active at elevated temperature
US4948875 Nov 20, 1987 Aug 14, 1990 Suntory Limited Novel polypeptide having an anti-tumor activity and a method of preparation thereof
US4963354 Jan 21, 1987 Oct 16, 1990 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5098702 Jun 26, 1989 Mar 24, 1992 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5155027 May 2, 1989 Oct 13, 1992 Zymogenetics, Inc. Method of producing secreted receptor analogs and biologically active peptide dimers
US5211945 Sep 9, 1987 May 18, 1993 Yeda Research And Development Co. Ltd. Compositions and methods for modulating the effect of tnf and il-1
US5264416 Jun 1, 1992 Nov 23, 1993 Immunex Corporation Interleukin-7 receptors
US5270038 Jan 23, 1992 Dec 14, 1993 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
US5359032 Dec 1, 1992 Oct 25, 1994 Biogen Inc. Interkeukin-1 inhibitor
US5639597 May 13, 1994 Jun 17, 1997 Behringwerke Aktiengesellschaft Cell-free receptor binding assays, the production and use thereof
US5811261 * Sep 24, 1993 Sep 22, 1998 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5945397 May 16, 1996 Aug 31, 1999 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6143866 Jan 19, 1995 Nov 7, 2000 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US20030064480 Apr 30, 2002 Apr 3, 2003 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
AU58976A Title not available
EP0227110A2 Dec 23, 1986 Jul 1, 1987 Teijin Limited Human immunoglobulin G FC region protein and production thereof
EP0230574A2 Dec 4, 1986 Aug 5, 1987 Yale University Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof
EP0269455A2 Nov 27, 1987 Jun 1, 1988 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human IgE Fc fragment and production thereof
EP0325224A2 Jan 18, 1989 Jul 26, 1989 ZymoGenetics, Inc. Methods of producing secreted receptor analogs and biologically active peptide dimers.
EP0325262A2 Jan 20, 1989 Jul 26, 1989 The General Hospital Corporation Cloned genes encoding IG-CD4 fusion proteins and the use thereof
EP0394827A1 Apr 19, 1990 Oct 31, 1990 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0414178A2 Aug 18, 1990 Feb 27, 1991 The General Hospital Corporation Non-human primate CD4 polypeptides and human CD4 molecules capable of being glycosylated
EP0460846A1 May 24, 1991 Dec 11, 1991 Immunex Corporation Type II interleukin-1 receptors
EP0471701A1 May 4, 1990 Feb 26, 1992 Basf Ag Novel tnf-inhibit proteins and their preparation.
EP0526452A1 Nov 21, 1990 Feb 10, 1993 Genentech, Inc. Hybrid immunoglobulins
EP0567566B1 Jan 17, 1992 Mar 15, 2000 Amgen Inc. Methods for treating tumor necrosis factor mediated diseases
EP0568925A2 Apr 29, 1993 Nov 10, 1993 Yeda Research And Development Co. Ltd. TNF receptor action modulation
EP0606869A1 Jan 10, 1994 Jul 20, 1994 Yeda Research And Development Company, Ltd. Promotor sequence of the p55 tumor necrosis factor receptor
JPH02154695A Title not available
JPS61293924A Title not available
WO1989009622A1 Apr 13, 1989 Oct 19, 1989 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1991017184A1 Apr 3, 1991 Nov 14, 1991 The Upjohn Company Modified interleukin-1 inhibitors
1 Abraham et al., Lenercept (p55 Tumor Necrosis Factor Receptor Fusion Protein) In Severe Sepsis and Early Septic Shock: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial With 1,342 Patients, Crit Care Med, 29:503-510 (2001).
2 Abraham et al., p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: JAMA, 19:1531-1538 (1997).
3 Abstract 92-009794/02 (1992) for EP 464 533.
4 Abstract by Heller et al., Napa Valley Conference (1989).
5 Aggarwal et al., Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by gamma-Interferon, Nature, 318:665-667 (1985).
6 Aggarwal et al., Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by γ-Interferon, Nature, 318:665-667 (1985).
7 Aggarwal et al., Human tumour necrosis factors: structure and receptor interactions, in Tumor necrosis factor and related cytotoxins, pp. 39-51, (Ciba Foundation symposium 131), Wiley, Chichester (1987).
8 Aggarwal et al., Induction of Receptors for Tumor Necrosis Factor-alpha by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response, J. Biol. Chem., 262:10000-10007 (1987).
9 Aggarwal et al., Induction of Receptors for Tumor Necrosis Factor-α by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response, J. Biol. Chem., 262:10000-10007 (1987).
10 AHP Comments on Oral Hearing and Preliminary Opinion, dated Sep. 22, 2006.
11 AHP Response to Opponent's Observations, dated Oct. 6, 2006.
12 Answer of the Opponent on the Admissibility of the Oppositions, dated Nov. 3, 2004.
13 Arenzana-Seisdedos et al., Immunoregulatory Mediators in the Pathogenesis of Rheumotoid Arthritis, Scand. J. Rheumatol., Supplement 66:13-17 (1987).
14 Arora et al., "Differences in Binding and Effector Functions Between Classes of TNF Antagonists," Cytokine 45: 124-131 (2009).
15 Aruffo et al., "CD44 Is the Principal Cell Surface Receptor for Hyaluronate," Cell 61:1303-1313 (1990).
16 Aruffo et al., Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System, Proc. Natl. Acad. Sci. USA, 84:8573-8577 (1987).
17 Ashkenazi et al., Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin, Proc. Natl. Acad. Sci., U.S.A. 88:10535-10539 (1991).
18 Avis, Kenneth, Parental Preparations, Remington Pharmaceutical Sciences, Chapter 85, pp. 1518-1541 (1985).
19 Ayala, Modem Genetics, Benjamin/Cummings, Publ. Co., Menlo Park CA, p. 45, (1980).
20 Baglioni et al., Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition, J. Biol. Chem., 260:13395-13397 (1985).
21 Barone et al., Arthritis Rheum., 42(9)Suppl, Sep. 1999, Abstract 116.
22 Barone et al., Comparative Analysis of the Ability of Entanercept and Inflixamab to Lyse TNF-Expressing Cells in a Complement-Dependent fashion, Arthritis Rheum., v42(9) supplement, Sep. 1999.
23 Benjamini et al., Antibody Structure, in Immunology: A Short Course, 3rd ed., Wiley-Liss New York, 61-69 (1996).
24 Branellec et al., TNF: Antitumoral Agent at the Border Lines of Immunity and Inflammation, Path. Biol., 39:230-239 (1991).
25 Brennan et al., "Inhibitory Effects of TNF alpha Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," The Lancet 2(8657):244-247 (1989).
26 Brennan et al., "Inhibitory Effects of TNF α Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," The Lancet 2(8657):244-247 (1989).
27 Bringman, Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma, 6(5):489-507 (1987).
28 Brockhaus et al., Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies, Proc. Natl. Acad. Sci. USA, 87:3127-3131 (1990).
29 Byrn et al., Biological properties of a CD4 Immunoadhesin, Nature, 344:667-670 (Apr. 1990).
30 Byrn, et al., Nature, 344, pp. 667-670 (1990).
31 C. A. Smith et al, Science, vol. 248, pp. 1019-1023, (May 1990).
32 Capon et al., "Desiging CD4 immunoadhesins for AIDS therapy", Nature 337:525-530 (Feb. 9, 1989).
33 Capon, Designing CD4 Immunoadhesions for AIDS Therapy, Nature, 337:525-531 (1989).
34 Carpenter et al., Epidermal Growth Factor, J. Biol. Chem., 265:7709-7712 (1990).
35 Carpenter, Receptors for Epidermal Growth Factor and Other Polypeptide Mitogens, Ann. Rev, Biochem., 56:881-914 (1987).
36 Carter et al., Purification, Cloning, Expression and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein, Nature, 344:633-638 (1990).
37 Casadei et al., Expression and Secretion of Aequorin as a Chimeric Antibody by Means of a Mammalian Expression Vector, Proc. Natl. Acad. Sci., U.S.A. 87:2047-2051 (1990).
38 Center for Drug Evaluation and Research, Guidelines on Sterile Drug Products Produced by Aseptic Processing, Published by the FDA Jun. 1987.
39 * Chan et al. 2000, Science, 288: 2351-2354.
40 Coffman et al., The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation, Immunol. Rev., 102:5-28 (1988).
41 Creasey et al., A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated With Cytotoxicity, Proc. Natl. Acad. Sci. USA, 84:3293-3297 (1987).
42 D. Novick et al, J. Exp. Med., vol. 170, pp. 1409-1414, (1988).
43 Dayer, Chronic Inflammatory Joint Diseases: Natural Inhibitors of Interleukin 1 and Tumor Necrosis Factor alpha, J. Rheumatol, 18 (Suppl. 27): 71-75 (1991).
44 Dayer, Chronic Inflammatory Joint Diseases: Natural Inhibitors of Interleukin 1 and Tumor Necrosis Factor α, J. Rheumatol, 18 (Suppl. 27): 71-75 (1991).
45 Declaration of Taruna Arora, PH.D. Under 37 C.F.R. 1.132 with Exhibits A-D, Dec. 16, 2010.
46 * Dembic et al, 1990. Cytokine. 2(4): 231-7.
47 Dembie, Z., et al., Cytokine, 2, pp. 231-237 (1990).
48 Dower et al., Human Cytokine Receptors, J. Clin. Immunol., 10:289-299 (1990).
49 Eisenberg et al., Primary Structure and Functional Expression From Complementary DNA of a Human Interleukin-1 Receptor Antagonist, Nature, 343:341-346 (1990).
50 Ellison et al., The Nucleotide Sequence of a Human Immunoglobulin Cγ1 Gene, Nucleic Acids Res. 10(13): 4071-79 (1982).
51 Engelmann et al., "A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity", J. Bio. Chem. 264:11974-11980 (1989).
52 Engelmann et al., "Antibodies to a s luble f rm f a tumor necrosis factor (TNF) receptor have TNF-like activity", J. Bio. Chem. 265:14497-14504 (1990).
53 Engelmann et al., "Two tum r necr sis factor-binding proteins purified from human urine", J. Bio. Chem. 265:1531-1536 (1990).
54 Esmon, The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation, J. Biol. Chem., 264:4743-4746 (1989).
55 Espevik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor", J. Exp. Med. 171:415-426 (1990).
56 European Search Report for EP 97 12 0664, dated Mar. 9, 1998.
57 Evans, T.J. et al., J. Exp. Med. 180, pp. 2173-2179 (1994).
58 Feldmann et al., "Cytokine production in the rheumatoid joint: implications for treatment," Ann. Rheum. Dis. 49: 480-486 (1990).
59 Fell et al., Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab′) With Specificity for Carcinomas and Human IL-2, J. Immunol., 146:2446-2452 (1991).
60 Fernandez-Botran et al., A Soluble, High-Affinity, Interleukin-4-Binding Protein is Present in the Biological Fluids of Mice, Proc. Natl. Acad. Sci., 87:4202-4206 (1990).
61 Fernandez-Botran, Soluble Cytokine Receptors: Their Role in Immunoregulation, The FASEB Journal, 5:2567-2574 (1991).
62 Ferrante et al., Inhibition of Tumour Necrosis Factor Alpha (TNF-α)-Induced Neutrophil Respiratory Burst by a TNF Inhibitor, Immunology, 72:440-442 (1991).
63 Final Office action dated Jun. 24, 2011, in U.S. Appl. No. 08/444,791 (Brockhaus, et al.).
64 Fisher et al., Cloning and Expression of Human Tissue Factor cDNA, Thrombosis Research, 48:89-99 (1987).
65 Fisher, et al., N. Engl. J. of Med. 334, pp. 1697-1702 (1996).
66 Foley et al., An Inhibitor of the Toxicity of Tumour Nectrosis Factor in the Serum of Patients With Sarcoidosis, Tuberculosis and Crohn's Disease, Clin. Exp. Immunol, 80:395-399 (1990).
67 Folks et al., Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone, PNAS, 86:2365-8 (1989).
68 Fomsgaard et al., Preliminary Study on Treatment of Septic Shock Patients With Antilipopolysaccharide IgG from Blood Donors, Scand. J. Infect. Dis., 21:697-708 (1989).
69 Furst et al., "Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection," Semin. Arthritis Rheum. 36: 159-167 (2006).
70 Garcia et al., High Sensitivity of Transgenic Mice Expressing Soluble TNFR1 Fusion Protein to Mycobacterial Infections: Synergistic Action of TNF and IFN-γ in the Differentiation of Protective Granulomas, Eur. J. Immunol., 27:3182-3190 (1997).
71 Gascoigne et al., Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein, Proc. Natl. Acad. Sci USA, 84:2936-2940 (1987).
72 Gehr et al., Both Tumor Necrosis Factor Receptor Types Mediate Proliferative Signals in Human Mononuclear Cell Activation, J. Immunol., 149:911-917 (1992).
73 Gen Seq DBase Printout.
74 Gillies et al., Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells, J. Immunol., 144:1067-1071 (1991).
75 Goodman, Identification of Antigenic Determinants, in Basic & Clinical Immunol., 24-25 (1982).
76 Goodman, Immunogenicity & Antigenic Specificity, in Basic & Clinical Immunol., 101-108 (1991).
77 Goodwin et al., Molecular cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor, Molecular and Cellular Biology, 11:3020-3026 (1991).
78 Gray et al, Cloning and Expression of cDNA for Human Lymphotoxin, a Lymphokine With Tumour Necrosis Activity, Nature, 312:721-724 (1984).
79 Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein", Proc. Natl. Sci. USA 87:7380-7384 (1990).
80 Grundmann et al., Characterization of cDNA Coding for Human Factor XIIIa, Proc. Natl. Acad. Sci. USA, 83:8024-8028 (1986).
81 H. Engelmann et al., Jour. of Biological Chemistry, vol. 264, Nr. 20, p. 11974-11980, (Jul. 1989).
82 H. Engelmann et al., Jour. of Biological Chemistry, vol. 264, p. 531-1536, (Jan. 1990).
83 H. Loetscher et al,. Cell, vol. 61, p. 351-359 (Apr. 1990).
84 Haak-Frendscho et al., Inhibition of TNF by a TNF Receptor Immunoadhesin, J. Immunol., 152:1347-1353 (1994).
85 Hannum et al., Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor, Nature, 343:336-340 (1990).
86 Heflin et al., Prevention by Granulocyte Depletion of Increased Vascular Permeability of Sheep Lung Following Endotoxemia, J. Clin. Invest., 68:1253-1260 (1981).
87 Heller et al., "Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected with Epstein-Barr Virus Shuttle Vector cDNA Libraries," J. Biol. Chem. 265(10): 5708-5717 (1990).
88 Heller et al., "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor", Proc. Natl. Acad. Sci. U.S.A. 87:6151-6155 (1990).
89 Heller et al., Abstract at the 2nd International Conference on Tumor Necrosis Factor and Related Cytokines, Napa Valley, California, Jan. 15-20, 1989.
90 Heller et al., JBC 265(10): 5708-5717 (1990).
91 Himmler et al., Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein, DNA and Cell Biology, 9:705-715 (1990).
92 Hobart, The Immune System: A Course on the Molecular and Cellular Basis of immunity, Blackwell Scientific Pubs, p. 7 (1975).
93 Hohmann et al., "Expression of the types A and B tumor necrosis factor (TNT) recept rs is independently r gulated, and both receptors mediate activation of the transcription factor NF-kB", J. Bi . Chem. 265:22409-22417 (1990).
94 Hohmann et al., "Two different cell types have different major r cept rs f r human tumor necr sis factor (TNFalpha)", J. Bio. Chem. 264:14927-14934 (1989).
95 Hohmann et al., "Two different cell types have different major r cept rs f r human tumor necr sis factor (TNFα)", J. Bio. Chem. 264:14927-14934 (1989).
96 Holtmann et al., Down Regulation of the Receptors for Tumor Necrosis Factor by Intereukin 1 and 4β-Phorbol-12-Myristate-13-Acetate, J. Immunol., 139:1161-1167 (1987).
97 Hoogenboom et al., "Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins," Molecular Immunol. 28(9): 1027-1037 (1991).
98 Hsu, et al., J. Biol. Chem. 268, pp. 16430-16436 (1993).
99 Idzerda et al., Human Interleukin 4 Receptor Confers Biological Responsiveness and Defines a Novel Receptor Superfamily, J. Exp. Med., 171:861-873 (1990).
100 Imamura et al., Expression of Tumor Necrosis Factor Receptors on Human Monocytes and Internalization of Receptor Bound Ligand, J. Immunol., 139:2989-2992 (1987).
101 Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (2003).
102 Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (Mar. 2003).
103 IPS Notice of Opposition to EP 0 939 121 and Statement in Support of the Opposition against EP 0939121, Dec. 30, 2003.
104 Irwin and Tipton, Chapter 22, "Affinity Precipitation Methods" in Methods in Mol. Bio., 59:217 (1996).
105 Ishikura et al., Differential Biologic Effects Resulting From Bimodal Binding of Recombinant Human Tumor Necrosis Factor to Myeloid Leukemia Cells, Blood, 73:419-424 (1989).
106 Israel et al., Binding of Human TNF-α to High-Affinity Cell Surface Receptors: Effect of IFN, Immunology Letters, 12:217-224 (1986).
107 Jacobs et al., Pharmacokinetic Parameters and Biodistribution of Soluble Cytokine Receptors, International Review of Expermental Pathology, 34B:123-135 (1993).
108 Jones et al, Structure of Tumour Necrosis Factor, Nature, 338:225-228 (1989).
109 Kaczmarski et al., The Cytokine Receptor Superfamily, Blood Reviews, 5:193-203 (1991).
110 Kaushansky, Structure-Function Relationships of the Hematopoietic Growth Factors, Proteins: Structure, Function & Genetics, 12:1-9 (1992).
111 Keegan et al., Interleukin 4 Receptor: Signaling Mechanisms, Immunology Today, 15:423-432 (1994).
112 Keegan et al., The Interleukin-4 Receptor. Signal Transduction by a Hematopoietin Receptor, Journal of Leukocyte Biology, 55:272-279 (1994).
113 Khare et al, Poster 715 presented at the Annual Meeting of the Society for Investigative Dermatology (SID), May 3-5, 2006, Philadelphia, PA.
114 Klein, Immunology, 1st Edition, Klein ed., Blackwell Scientific Publications, Cambridge, MA 1990 at pp. 446-447.
115 Kleinau et al., Importance of CD23 for Collagen-Induced Arthritis: Delayed Onset and Reduced Severity in CD23-Deficient Mice, J. Immunol., 162:4266-4270 (1999).
116 Klinkert et al., TNF-α Receptor Fusion Protein Prevents Experimental Auto-Immune Encephalomyelitis and Demyelination in Lewis Rats: an Overview, The Journal of Neuroimmunology, 72:163-168 (1997).
117 Kohno et al., A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor, Proc. Natl. Acad. Sci. USA, 87:8331-8335 (1990).
118 Kohno et al., Presentation 1495, poster 271 presented at American College of Rheumatology Annual Meeting, Nov. 13-17, 2005, San Diego, CA.
119 Kruse et al., Conversion of Human Interleukin-4 Into a High Affinity Antagonist by a Single Amino Acid Replacement, The EMBO Journal, 11:3237-3244 (1992).
120 Kull et al., Cellular Receptor for 125I-Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity, Proc. Natl. Acad. Sci. USA, 82:5756-5760 (1985).
121 Landolfi, A Chimeric IL-2/Ig Molecule Possesses the Functional Activity of Both Proteins, J. Immunol., 146:915-919 (1991).
122 Langner et al., Structural and Functional Analysis of a TNF Receptor-Immunoglobulin Fusion Protein, New Advances on Cytokines, 349-354 (1992).
123 Larsson and Mosbach, Affintiy Precipitation of Enzymes FEBS Lett. 98(2):333-338 (1979).
124 Leberthon et al., Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate, Cancer Research, 51:2694-2698 (1991).
125 Lee, Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase, Science, 239:1288-1291 (1988).
126 Lesslauer et al., Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality, Eur. J. Immunol., 21:2883-2886 (1991).
127 Letter to the EPO with new Auxiliary request 3 in appeal proc. against EP 0 471 701, Dec. 31, 2001.
128 Liabakk et al., A Rapid and Sensitive Immunoassay for Tumor Necrosis Factor Using Magnetic Monodisperse Polymer Particles, Journal of Immunological Methods, 134:253-259 (1990).
129 Loetscher et al, J. of Bio. Chem., 266(27), pp. 18324-18329, (1991).
130 Loetscher et al., "Molecular cloning and expression of the human 55 kd tum r necrosis fact r rec ptor", Cell 61:351-359 (1990).
131 Loetscher et al., Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock, Endotoxin Research Series, 2:455-462•1993).
132 Loetscher et al., Two Distinct Human TNF Receptors: Purification, Molecular Cloning and Expression, 3rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Japan, Nov. 21-25, 1990.
133 Loetscher et al., Two distinct human TNF receptors: purification, molecular cloning and expression, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3rd International Conference, 1992.
134 Maliszewski et al., Cytokine Receptors and B Cell Functions: Recombinant Soluble Receptors Specifically Inhibit IL-1 and IL-4 Induced Cell Activities In Vitro, J. Immunol., 144:3028-3033 (1990).
135 * Miles JS, et al. Principles of DNA cloning. British Medical Journal. 1989 299:1019-1022.
136 Mitoma et al., "Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on Transmembrane Tumor Necrosis Factor alpha-Expressing Cells," Arthr. & Rheum. 58(5): 1248-1257 (2008).
137 Mitoma et al., "Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on Transmembrane Tumor Necrosis Factor α-Expressing Cells," Arthr. & Rheum. 58(5): 1248-1257 (2008).
138 Mohler et al., Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists, J. Immunol., 151:1548-1561 (1993).
139 Mohler et al., Soluble Tumor NecrosisFfactor (TNF) Receptors are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists. J. Immunol., 151:1548-1561 (1993).
140 Monnat, "Molecular Analysis of Spontaneous Hypoxanthine Phosphoribosyltransferase Mutations in Thioguanine-resistant HL-60 Human Leukemia Cells," Cancer Res. 49:81-87 (1989).
141 Moreland et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, New England Journal of Medicine, 337:141-147 (1997).
142 Mori et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 157:3178-3182 (1996).
143 Morrison, In Vitro Antibodies: Strategies for Production and Application, Annu. Rev. Immunol., 10:239-265 (1992).
144 Morrissey et al., Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade, Cell: 50:129-135 (1987).
145 Mosley et al., The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms, Cell: 59:335-348 (1989).
146 Nature Biotechnology, 15 (1997) p. 13.
147 Nesbitt, et al., "Mechanism of Action of Certolizumab Pegol (Cdp870): In Vitro Comparison With Other Anti-Tumor Necrosis Factor alpha Agents", Inflamm Bowel Dis, 13: 1323-1332 (Nov. 2007).
148 Nesbitt, et al., "Mechanism of Action of Certolizumab Pegol (Cdp870): In Vitro Comparison With Other Anti-Tumor Necrosis Factor α Agents", Inflamm Bowel Dis, 13: 1323-1332 (Nov. 2007).
149 Nophar et al., EMBO J., 9:3269-3278 (1990).
150 Notification of the Examiner during the prosecution of EP 99100703.0, Oct. 24, 2000.
151 Novick et al., "Soluble cytokine receptors are present in normal human urine", J. Exp. Med. 170:1409-1414 (1989).
152 Novotny et al., A Soluble, Single-Chain T-Cell Receptor Fragment Endowed With Antigen-Combining Properties, Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991).
153 Official Communication relating to an Opposition in EP Application No. 99 100 703.0, Jan. 31, 2006.
154 Okayama et al., A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells, Molecular and Cellular Biology, 3:280-289 (1983).
155 Okayama et al., High-Efficiency Cloning of Full-Length cDNA, Molecular and Cellular Biology, 2:161-170 (1982).
156 Old, Tumor Necrosis Factor, 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 1-30 (1989).
157 Olsson et al., "Isolation and characterization of a tumor necrosis factor binding pr tein fr m urin ", Eur. J. Ha matol. 42:270-275 (1989).
158 Olsson et al., Eur. J. Haematol., 42: 270-275 (1989).
159 * Olsson, I, et al., Isolation and charaterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989;42:270-275.
160 Opponent's Observations Under R 71a EPC, dated Sep. 22, 2006.
161 P. Seckinger et al, Eur. J. Immunology, vol. 20, pp. 1167-1174 (1990).
162 P. Seckinger et al., Jour. of Biological Chem., vol. 264, pp. 22966-11973 (Jul. 1989).
163 P.W. Gray et al, Proc. of the Nat'l Acad. of Sci., vol. 87, p. 7380-7884, (Oct. 1990).
164 Paborsky et al., Purification of Recombinant Human Tissue Factor, Biochemistry, 28:8072-8077 (1989).
165 Parrillo, Pathogenetic Mechanisms of Septic Shock, New Eng. J. Med., 328:1471-1477 (1993).
166 Patentee's Response to Notice of Opposition Request for Oral Hearing, dated Aug. 3, 2004 (with translation).
167 Paul et al., Fundamental Immunology, 2nd Edition, Paul, ed., Raven Press, New York, 1989, at pp. 679-701 and pp. 735-764.
168 Peetre et al., A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids, Eur. J. Haematol. 41:414-419 (1988).
169 Pennica et al., Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin, Nature, 312:724-729 (1984).
170 Peppel et al., "Chimaeric TNF-receptor-IgG molecule acts as soluble inhibitor of TNF mediated cytotoxicity", Journal of Cellular Biochem., Abstract, 20th Annual Meetings, Keystone Symposia on Molecular and Cellular Biology, p. 118, Supplement 15F (1991).
171 Peppel et al., "Chimaeric TNF-receptor—IgG molecule acts as soluble inhibitor of TNF mediated cytotoxicity", Journal of Cellular Biochem., Abstract, 20th Annual Meetings, Keystone Symposia on Molecular and Cellular Biology, p. 118, Supplement 15F (1991).
172 Peppel, K., et al., J. Exp. Med., 174, pp. 1483-1489 (1991).
173 Piguet et al., Evolution of Collagen Arthritis in Mice is Arrested by Treatment With Anti-Tumor Necrosis (TNF) Antibody or a Recombinant Soluble TNF Receptor, Immunology, 77 (4):510-514 (1992).
174 Porteu and Nathan, "Shedding of tumor necrosis factor receptors by activated human neutrophils", J. Exp. Med. 172:599-607 (1990).
175 R. A. Heller et al., Proc. of the Nat'l Acad. of Sci., vol. 87, pp. 6151-6155, (Aug. 1990).
176 Redfield'et al., Secondary Structure and Topology of Human Interleukin 4 in Solution, Biochemistry, 30:11029-11035 (1991).
177 Response to Patentee's Written Submission, dated Jul. 22, 2005.
178 Rubin, Binding Receptor Characters Zako and Expression, and Intracellular Events. 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 94-96 (1989).
179 Ruddle et al., An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis, J. Exp. Med., 172:1193-1200 (1990).
180 Rutka et al., The Effects of Human Recombinant Tumor Necrosis Factor on Glioma-Derived Cell Lines: Cellular Proliferation, Cytotoxicity, Morphological and Radioreceptor Studies, Int. J. Cancer., 41:573-582 (1988).
181 Sandborn et al., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterol., 121:1088-94 (2001).
182 Saxne et al., Detection of Tumor Necrosis Factor α But Not Tumor Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum, Arthritis & Rheumatism, 31:1041-1045 (1988).
183 Scallon et al., Functional Comparisons of Different Tumour Necrosis Factor Receptor/IgG Fusion Proteins, Cytokine, 7:759-770 (1995).
184 Scarpati et al., Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene, Biochemistry, 26:5234-5238 (1987).
185 Schall et al., "Molecular cloning and expression of a receptor for human tumor necrosis factor", Cell 61:361-370 (1990).
186 Schleiffenbaum et al., The Tumor Necrosis Factor Receptor and Human Neutrophil Function, J. Clin. Invest., 86:184-195 (1990).
187 Schnee et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, Proc. Natl. Acad. Sci. USA, 84:6904-6908 (1987).
188 Seckinger et al., "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-activity with the TNF receptor", Proc. Natl. Sci. USA 87:5188-5192 (1990).
189 Seckinger et al., "Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-activity with the TNF receptor", Proc. Natl. Sci. USA 87:5188-5192 (1990).
190 Seckinger et al., "Purification and biologic characterization of a sp cific tum r necrosis fact r alpha inhibitor", J. Bio. Chem. 264:11966-11973 (1989).
191 Seckinger et al., "Purification and biologic characterization of a sp cific tum r necrosis fact r α inhibitor", J. Bio. Chem. 264:11966-11973 (1989).
192 Seckinger et al., "Tumor necrosis factor inhibitor: purification, NH3-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities", Eur. J. Immunol. 20:1167-1174 (1990).
193 Seckinger et al., A Human Inhibitor of Tumor Necrosis Factor α, J. Exp. Med. 167:1511-1516 (1988).
194 Sell, Immunology, Immunopathology and Immunity, 4th Edition, Elsevier Science Publishing Co., New York, 1987, at pp. 85-91.
195 Shalaby et al., "The Involvement of Human Tumor Necrosis Factors-alpha and -betain the Mixed Lymphocyte Reaction," J. Immunol. 141:449-503 (1988).
196 Shalaby et al., "The Involvement of Human Tumor Necrosis Factors-α and -βin the Mixed Lymphocyte Reaction," J. Immunol. 141:449-503 (1988).
197 Shalaby et al., Binding and Regulation of Cellular Function by Monoclonal antibodies Against Human Tumor Necrosis Factor Receptors, J. Exp. Med. 172: 1517-1520 (1990).
198 Shalaby et al., Receptor Binding and Activation of Polmorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha, Journal of Leukocyte Biology, 41:196-204 (1987).
199 Sheehan et al., Generation and Characterization of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors, Journal of Immunology, 142:3884-3893 (1989).
200 Shin et al., Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-Like Growth Factor 1: Potential Applications for Cellular Targeting, Proc. Natl. Acad. Sci., 87:5322-5326 (1990).
201 Sims et al., cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily, Science, 241:585-589 (1988).
202 Sims et al., Cloning the Interleukin 1 Receptor From Human T Cells, Proc. Natl. Acad. Sci., 86:8946-8950 (1989).
203 Smith and Baglioni, The ActiveFform of Tumor Necrosis Factor is a Trimer J. Biological Chemistry, 262:6951-4 (1987).
204 * Smith et al, 1989. Journal of Biological Chemistry. 14646-15652.
205 Smith et al., A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins, Science, 248:1019-1023, (1990).
206 Smith et al., Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen, Science, 238:1704-1707 (1987).
207 Smith et al., Multimeric Structure of the Tumor Necrosis Factor Receptor of HeLa Cells, J. Biol. Chem., 264:14646-14652 (1989).
208 Smith et al., The Active Form of Tumor Necrosis Factor is a Trimer, J. Biol. Chem., 262:6951-6954 (1987).
209 Smith t al., "A receptor for tum r necrosis factor defines an unusual family of cellular and viral proteins", Scienc 248:1019-1023 (1990).
210 Smitii, "cDNA Expression: Cloning of the Receptor for Human Tumor Necrosis Factor," Presentation Programme, 29th Midwinter Conference of Immunologists (Jan. 27-30, 1990).
211 Spicer et al., Isolation of cDNA Clones Coding for Human Tissue Factor: Primary Structure of the Protein and cDNA, Proc. Natl. Acad. Sci., 84:5148-5152 (1987).
212 Staines et al., Collagen Arthritis—What Can It Teach Us?, British Journal of Rheumatology, 33:798-807 (1994).
213 Stauber et al., "Human tumor necrosis factor-alpha receptor-purification by immunoaffinity chromatography and initial characterization", J. Bio. Chem. 263:19098-19104 (1988).
214 Stauber et al., "Human tumor necrosis factor-α receptor—purification by immunoaffinity chromatography and initial characterization", J. Bio. Chem. 263:19098-19104 (1988).
215 Strader et al., Structural Basis of β-Adrenergic Receptor Function, The FASEB Journal, 3:1825-1832 (1989).
216 Strangfeld et al., "Risk of Herpes Zostcr in Patients with Rheumatoid Arthritis Treated with Anti-TNF-alpha Agents," JAMA 301(7): 737-744 (2009).
217 Strangfeld et al., "Risk of Herpes Zostcr in Patients with Rheumatoid Arthritis Treated with Anti-TNF-α Agents," JAMA 301(7): 737-744 (2009).
218 Suggs et al., Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β2,-Microglobulin, Proc. Natl. Acad. Sci. U.S.A., 78:6613-6617 (1981).
219 T.J. Schall et al., Cell, vol. 61, p. 361-370 (Apr. 1990).
220 Tauber et al., Toxicity in Neuronal Cells Caused by Cererospinal Fluid fFom Pneumococcal and Gram-Negative Meningitis, The Journal of Infectious Diseases, 166:1045-1050 (1992).
221 Thoma et al., Identification of a 60-kD Tumor Necosis Factor (TNF) Receptor as the Major Signal Transducing Component in TNF Responses, J. Exp. Med. 172: 1019-23 (1990).
222 Traunecker et al., Highly Efficient Neutralization of HIV with Recombinant CD-4-Immunoglobulin Molecules, Nature 339:68-70, 1989.
223 Traunecker, A. et al., Nature, 339, pp. 68-70 (1989).
224 Tsujimoto et al, Interferon-γ Enhances Expression of Cellular Receptors for Tumor Necrosis Factor, J. Immunol., 136:2441-2444 (1986).
225 Tsujimoto et al, Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells, Proc. Natl. Acad. Sci. 82: 7626-30 (1985).
226 Tsujimoto et al., Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells, Archives of Biochemistry and Biophysics, 249:563-568 (1986).
227 U.S. Appl. No. 07/555,274, filed Jul. 19, 1990, Kohno et al.
228 U.S. Appl. No. 08/444,791-Office Action mailed Jun. 8, 2010.
229 U.S. Appl. No. 08/444,791—Office Action mailed Jun. 8, 2010.
230 U.S. Appl. No. 08/444,791-Office Action mailed Oct. 15, 2010.
231 U.S. Appl. No. 08/444,791—Office Action mailed Oct. 15, 2010.
232 U.S. Appl. No. 08/478,995, Lauffler, Leander et al.
233 U.S. Appl. No. 08/484,783, filed Jun. 7, 1995, Kohno et al.
234 Ulich et al., Intratracheal Administration of Endotoxin and Cytokines, Clinical Immunology & Immunopathology., 72:137-140 (1994).
235 Unglaub et al., Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators, J. Exp. Med. 166:1788-1797 (1987).
236 US 6,224,867, 05/2001, Smith et al. (withdrawn)
237 Van Der Poll et al., Pretreatment with a 55-kDa Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Attenuates Activation of Coagulation, but not of Fibrinolysis, during Lethal Bacteremia in Baboons, The Journal of Infectious Diseases., 176:296-299 (1997).
238 Van Zee et al., Protection Against Lethal Escherichia coli Bacteremia in Baboons (Papio anubis) by Pretreatment With a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081, J. Immunol., 156:2221-2230 (1996).
239 Wallach et al., Cell surface and soluble TNF receptors, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Nov. 21-25, 1990), Osawa and Bonavida, eds., Basel, Karger, pp. 47-57 (1992).
240 Wallach et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Progress, Inflammation Research & Therapy, 51-57 (1991).
241 Wallis et al., "Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists," Clin. Inf. Dis. 38: 1261-1265 (2004).
242 Wallis et al., "Reactivation of Latent Granulomatous Infections by Infliximab," Clin. Inf. Dis. 41(Suppl 2): S1-S5 (2005).
243 Watson et al., "A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules," J. Cell Biol. 110:2221-2229 (1990).
244 Watson et al., "A Homing Receptor—IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules," J. Cell Biol. 110:2221-2229 (1990).
245 Wilks, The CD4 Receptor: Post Binding Events, Conformational Change and the Second Site, Molec. Aspects Med., 12:255-265 (1991).
246 Wingfield et al., Tumour Necrosis Factor is a Compact Trimer, FEBS Lett. 211: 179-84 (1987).
247 Winzor et al., "Evaluation of Equilibrium Constants from Precipitin Curves: Interaction of alpha -Crystallin with an Elicited Monoclonal Antibody," Arch. Biochem. Biophys. 268(1): 221-226 (1989).
248 Winzor et al., "Evaluation of Equilibrium Constants from Precipitin Curves: Interaction of α -Crystallin with an Elicited Monoclonal Antibody," Arch. Biochem. Biophys. 268(1): 221-226 (1989).
249 Wozney, Using purified protein to clone its genes, Methods in Enzymology, 182:738-751 (1990).
250 Yamasaki et al., Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) Receptor, Science, 241:825-282 (1988).
251 Yonehara et al., A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated With the Receptor of Tumor Necrosis Factor, J. Exp. Med., 169:1747-1765 (1989).
252 Yoshie et al., Binding and Crosslinking of 125I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors, J. Biochem., 100: 531-541(1986).
253 Zavoico, Drug & Market Development, 10(7):235-243 (1999).
254 Zettlmeissl, G., et al., DNA & Cell Biology, 9, pp. 347-353 (1990).
US9388240 Apr 24, 2015 Jul 12, 2016 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
US9518111 * Sep 5, 2014 Dec 13, 2016 Immunex Corporation Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein
US9580502 Jun 8, 2016 Feb 28, 2017 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
US20140377264 * Sep 5, 2014 Dec 25, 2014 Immunex Corporation Polypeptide Formulation
WO2014043103A1 Sep 10, 2013 Mar 20, 2014 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
U.S. Classification 530/350, 930/144, 536/23.5, 530/387.3
International Classification C07K16/28, A61P29/00, C07H21/04, C07K19/00, C07K14/715, A61K38/17
Cooperative Classification C07K14/7151, C07K16/2866, C12N2799/026, Y10S930/144
Free format text: TRIAL NO: IPR2017-02066